Reuters logo
BRIEF-Revance completes patient enrollment in Phase 2 program for RT002 injectable
2017年10月18日 / 下午1点25分 / 1 个月前

BRIEF-Revance completes patient enrollment in Phase 2 program for RT002 injectable

Oct 18 (Reuters) - Revance Therapeutics Inc

* Revance completes patient enrollment in Phase 2 program for RT002 injectable in the management of plantar fasciitis

* Revance therapeutics - on track to report 8-week topline results at end of the year, including primary, secondary endpoints, with safety data RT002​ for Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below